LUPUS ERYTHEMATOSUS, SYSTEMIC

This study is testing a single infusion of a genetically modified cell therapy called rapcabtagene autoleucel for adults with severe lupus or lupus kidney disease that hasn't responded to at least two standard treatments. The goal is to see if this one-time treatment can put the …

This study is testing if adding a new oral drug called cenerimod helps adults with moderate-to-severe lupus better control their disease. About 420 participants will take either cenerimod or a placebo pill for one year, in addition to their current lupus medications. The main goa…

This study is testing whether adding the experimental drug cenerimod to standard treatment helps adults with lupus nephritis, a serious kidney complication of lupus. About 300 participants will take either cenerimod or a placebo pill daily for about 1.5 years, alongside their reg…

This study is observing how well the drug anifrolumab works for people with systemic lupus in real-world Italian clinics. It aims to see if patients can achieve a state of very low disease activity while also reducing their daily steroid dose to 5mg or less. The study will follow…

This study is testing an experimental one-time treatment called CC-97540 for people with active systemic lupus erythematosus (SLE), including lupus affecting the kidneys. The treatment involves collecting and genetically modifying a patient's own immune cells (CAR T-cells) to tar…

This study aims to see how well the drug anifrolumab works for controlling lupus in real-world medical practice in Poland. It will follow 100 adult patients with lupus who are already receiving this medication through a national program for about 30 months. The main goal is to me…

This study is testing whether an experimental drug called nipocalimab can better control moderate to severe lupus compared to a placebo. It will involve 600 adults with active lupus over 52 weeks. The main goal is to see if the drug reduces overall disease activity while allowing…

This study is testing a new cell therapy called AZD0120 for adults with severe systemic lupus that hasn't responded well to other treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful cells that drive lupus. The first part of the stu…

This early-stage study is testing a new treatment called CTX112 for adults with severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle disease that haven't responded to standard therapies. The treatment uses genetically modified immune cells from healthy dono…

This study is testing whether a short, online behavioral therapy program delivered via Zoom can help adults with fibromyalgia, lupus, chronic pelvic pain, or chronic low back pain. The goal is to teach participants strategies to reduce their pain intensity, decrease pain-related …

This study aims to find a way to predict which cancer patients might develop serious side effects from immunotherapy drugs. Researchers will compare blood samples from 300 cancer patients starting immunotherapy with samples from 40 people who have autoimmune diseases. They are lo…

This study aims to understand how different compounds from the cannabis plant affect immune cells in a lab setting. Researchers will collect blood from 100 patients with chronic inflammatory diseases like rheumatoid arthritis and lupus. They will test various cannabis extracts on…